ReleaseWire

Nancy McFarlane, president of MedPro Rx, Inc. (http://www.medprorx.com), a provider of specialty pharmacy services to clients with chronic illnesses who need clotting factor, IVIg and other medication, has announced that the pharmacy awarded 49 scholarships in 16 states as part of its 2011 scholarship program. Since starting its “Education is Power” scholarship program in 2006, MedPro Rx has distributed nearly $300,000 to students nationwide who have either hemophilia or von Willebrand Disease (vWD). The annual scholarships are open to U.S. residents who are living with a bleeding disorder, entering or attending a community college, junior college, four-year college, university or vocational school, and active in their community.

Bob Martin Flea Spray is available in the Bob Martin Home Flea Spray 200ml and the Bob Martin Home Flea Spray Plus 500ml. The Bob Martin Home Flea Spray Kills fleas and ticks on contact in your home and goes on killing any new fleas brought into your home buy your pet for up to 3 months. It is clinically proven, kills mites and is designed for use on carpets, rugs and pet bedding. The Bob Martin Home Flea Spray Plus is a triple action home flea formula that kills adult fleas around the home for up to 3 months, plus stops fleas eggs and larvae developing for up to 12 months. It also kills house dust mites which can be a common cause of allergies in people and pets. Bob Martin Home Flea Spray Plus breaks the flea lifecycle, Kills fleas for up to 3 months, Stops flea egg development for up to 12 months and Kills house dust mites.

With key blockbuster drugs going off-patent in coming years, generics will account for around 80% of the total number of prescriptions dispensed in the US, says RNCOS in its latest report.

Clinical trials market now witnesses a paradigm shift. Naïve heterogeneous patient populations in the developing nations are opening up new avenues for the clinical trials market. Developing countries also offer faster means; which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the pharma-biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted.

The new XS2 Pharma Checkweigher has been designed with the specific needs of pharmaceutical brands in mind. The system offers precise product guidance and handling throughout the transfer process for increased weighing accuracy and exact product orientation.

Increasing collaborations pertaining to cancer generics drugs have intensified in the recent times, says RNCOS in its latest research study.

The biotech market in South Korea is forecasted to grow at a CAGR of around 35% during 2010-2013, says RNCOS in its latest research study.

The number of diabetes patients has been consistently increasing in Russia due to rapid adoption of modern ways of living, says RNCOS in its latest research study.

Nagoya University announces today it is presenting the NU Tech Regenerative Medicine Roundtable on October 6, 2011. The event will be held from 8 a.m. to 1:30 p.m. in the Hamner Conference Center auditorium at the North Carolina Biotechnology Center.

Evolve Selection are pleased to welcome on board our new Pilot Project Contract Sales team.

As the key blockbusters go off-patent in future, the share of generics in Indian pharmaceutical market will reach to 80.5% by FY 2013, says RNCOS in its latest research report.

Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930’s. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.

SK&A, A Cegedim Company, a leading provider of healthcare information solutions and research, today announced the results of a year-long survey to determine physician preferences for accepting drug sample packages provided by pharmaceutical companies.

Backed by factors like patent expiries of blockbuster drugs and strong demand, the Indian generics drug market will grow at a CAGR of 17% between FY 2011 and FY 2013.

The line between drug delivery and drug substance will continue to become more elusive in the near future as shown in the analysis in this report, as researchers work to improve drug properties through drug design and molecular modeling. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry.

As per our new research report, “Global Biosimilars Market Analysis”, the acceptability of biosimilars is very high in the Indian domestic market. Factors that are working favorably for Indian biosimilar companies are the relative cost advantage of biosimilar development compared to their competitors elsewhere; hence reducing appeal of imported biosimilars and relatively lowering of regulatory requirements for establishing bioequivalence.

METTLER TOLEDO has introduced OptiMax, a powerful synthesis workstation optimized for pharmaceutical, fine-chemical and specialty-chemical development. The unique design and its intuitive interface improves the organic synthesis process and maximizes time-to-result in product development in increasingly competitive markets. The compact workstation allows experiments to run from -40 to 180°C without oil or ice baths or bulky cryostats with little to no training.

The pharmaceutical market of Central & Eastern Europe is estimated at US$59.8 billion at retail prices in 2011; it is expected to reach US$94.5 billion by 2016. The market is expected to expand by a moderate CAGR of 7.7% in US dollar terms over the next few years as the region’s economies recover from the global economic crisis.

Backed by factors like patent expiration of drugs and aging population, the US generics market will grow at a CAGR of 10% during 2010-2013, says RNCOS.

Hetero Healthcare Limited, a leading Indian multi-national drug manufacturer, announced today the launching of KUTUB across India. KUTUB is now available at medical stores all over India.

GBI Research has released its latest report, “Emerging Market for Clinical Trials in Russia - Curbs on New Drug Approval Timelines and Registration Fees Encourage the Emergence of a Major Global Player” that provides key data, information and analysis of the major trends and issues affecting the Clinical Trial market in Russia. The report provides a comprehensive insight of reasons for outsourcing clinical trials to Russia. The report also provides a detailed analysis of Russian clinical trial market structure. Analysis of major companies and countries which sponsor clinical trials in Russia is provided. Patient population analysis is done to highlight the types of diseased population available for conducting clinical trials in Russia. Opinion of industry experts has been incorporated in various parts of the report to emphasize the importance of various factors that affect the clinical trial market scenario in Russia.

RNCOS has recently published “Ranbaxy Laboratories Limited - Company Analysis” The study provides an overview of the company’s history, businesses, its mergers and acquisitions, etc. It provides an insight into the products and services offered by the company for informing prospective clients about its product portfolio. The report also provides comprehensive financial information about the company to examine its financial health. Analytical tools such as Ratio analysis have been specifically designed to provide an idea about the fundamentals of the company. It will also help to analyze the company’s position with respect to the industry standards.

The prevalence of diabetes is less in China compared to other developed and developing nations, but as it houses the largest population in the world, it provides plethora of opportunities to the pharmaceutical players entering in this market. Besides, amid increasing concerns towards health and increasing awareness about chronic diseases, like diabetes among the consumers, the diabetic drug market is expected to show decent growth in the coming years. Consequently, the oral diabetic drug market in the country is anticipated to grow at a CAGR of around 5.3% during 2012 - 2014, says our new research report “China Diabetes Market Analysis”.

This TriMark Publications report describes the specific segment of the in vitro diagnostics (IVD) market known as drugs of abuse testing. In the current medical diagnostics market, drugs of abuse testing offers promise for significant growth and innovation. Examined in this study are assays for alcohol, cannabinoids, cocaine, amphetamines, opiates and phencyclidine, as well as assays for addictive prescription drugs such as OxyContin.